Eterna Therapeutics (ERNA)

P/S ratio as of November 2026 (TTM): N/A

According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.05. At the end of 2023 the company had a P/S ratio of 143.

P/S ratio history for Eterna Therapeutics from 2021 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	143
2022	N/A
2021	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Sanofi SNY	2.03	N/A	🇫🇷 France
Baxter BAX	1.19	N/A	🇺🇸 USA
Omeros Corporation OMER	33.1	N/A	🇺🇸 USA
Geron GERN	3.14	N/A	🇺🇸 USA
Genetic Technologies GENE	0.2168	N/A	🇦🇺 Australia
Teva Pharmaceutical Industries TEVA	2.90	N/A	🇮🇱 Israel
Bio-Techne TECH	9.41	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Eterna Therapeutics (ERNA)

P/S ratio as of November 2026 (TTM): N/A